Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Clinical trial NCT07342725 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07342725
- Sponsor
- Ruijin Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-01
- Primary completion
- 2027-12-31
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.